Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz, Karine Le Malicot, Bidaut Wahiba, Samy Louafi, Alain Gratet, Laurent Miglianico, H. Laharie, Karine Bouhier Leporrier, Anne Thirot Bidault, Patrick Texereau, Romain Coriat, Eric Terrebonne, Marie-Claude Gouttebel, David Malka, Jean‐Baptiste Bachet, Côme Lepage, Julien Taı̈eb, Cécile Julien, Nicolas M. Barrière, Julie Gigout, Simon Pernot, Céline Lepère, Aziz Zaanan, Géraldine Perkins, Raymond Despax, J. Chamois, Xavier Artignan, Pauline Regnault, Benoît Dupont, Maxime Lesouef, L. Bengrine Lefevre, Julie Vincent, François Ghiringhelli, Mme E. Barbier, Morgan Andre, Johann Dréanic, Catherine Brezault‐Bonnet, Valérie Boige, Antoine Holllebecque, B. Valenza, Gildas Phelip, Philippe Dominici, Marion Chauvenet, Frédérick Moryoussef, Pierre-Luc Etienne, Dominique Besson, Mathilde Martinez, Pamela Biondiani, Benoît Avisse, Marie‐Pierre Galais, Aurélie Parzy, Salvatore Caruso, Jean-François Codoul, Iulia Pripon, Mustapha Atlassi, Oana Cojocarasu, Etienne Suc, Ahmed Bedjaoui, Philippe Houyau, Yann Bergé, D. Gargot, Vincent Bourgeois, Pierre-Emmanuel Henneresse, S. Lavau Denes, Valérie Lebrun Lyat, Dominique Genet, Jean Martin, Pr Pierre Michel, David Sefrioui, Anne Escande, Louis-Marie Dourthe